NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
CLARITIN-D (loratadine and pseudoephedrine sulfate) by Bayer. Approved for these symptoms due to hay fever, other upper respiratory allergies: sneezing itchy, watery eyes runny nose itching of the nose and 4 more indications. First approved in 1994.
Drug data last refreshed 5h ago · AI intelligence enriched 7h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Claritin-D is an oral extended-release tablet combining loratadine (non-sedating antihistamine) and pseudoephedrine sulfate (nasal decongestant) for symptomatic relief of allergic rhinitis and upper respiratory congestion. It addresses sneezing, itching, watery eyes, runny nose, and nasal congestion associated with hay fever and common cold. The combination targets both histamine-mediated allergic symptoms and sympathomimetic nasal vasoconstriction.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team focus likely shifting to generic transition planning or line extension strategies rather than growth acceleration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CLARITIN-D at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.